Brief: Medicenna Therapeutics Says 100% Reduction Of Target Lesions In 1 Melanoma & 1 Pancreatic Cancer Patient Observed Among 4 Partial Responses
10/04/2024 11:39
April 10 (Reuters) - Medicenna Therapeutics Corp
MDNA.TO :
* MEDICENNA PRESENTS UPDATED RESULTS OF SINGLE AGENT MDNA11
ANTI-TUMOR ACTIVITY FROM DOSE ESCALATION AND ONGOING DOSE
EXPANSION OF THE PHASE 1/2 ABILITY-1 STUDY AT THE 2024 ANNUAL
MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)
* MEDICENNA THERAPEUTICS CORP: 100% REDUCTION OF TARGET
LESIONS IN
1 MELANOMA & 1 PANCREATIC CANCER PATIENT OBSERVED AMONG 4
PARTIAL RESPONSES TO DATE
* MEDICENNA THERAPEUTICS CORP: MDNA11 IS GENERALLY WELL
TOLERATED
Source text for Eikon: ID:nGNX3V7Bcl
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results